A novel SERPINE1‐FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K‐AKT‐mTOR signaling pathway and responsiveness to sirolimus-Reference-Cited by-同舟云学术

A novel SERPINE1‐FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K‐AKT‐mTOR signaling pathway and responsiveness to sirolimus

Published:2021-09-27 Issue:12 Volume:48 Page:1900-1906
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J. Dermatol.

Author:

Ren Jun¹^ORCID,Wang Xiaohui¹,Zhou Yulin²,Yue Xin³,Chen Shouhui⁴,Ding Xin⁴,Zeng Shengqiang⁵,Jiang Xiaoyong¹,Liu Xiaokun¹,Guo Qiwei²^ORCID

Affiliation:

1. Department of Dermatology Zhongshan Hospital Xiamen University Xiamen Fujian China

2. United Diagnostic and Research Center for Clinical Genetics, Women and Children’s Hospital School of Medicine & School of Public Health Xiamen University Xiamen Fujian China

3. Department of Radiology Zhongshan Hospital Xiamen University Xiamen Fujian China

4. Department of Pathology Zhongshan Hospital Xiamen University Xiamen Fujian China

5. The Graduate School of Fujian Medical University Fuzhou Fujian China

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.16158

Reference24 articles.

1. Pseudomyogenic Hemangioendothelioma

2. Primary Pseudomyogenic Hemangioendothelioma of Bone

3. The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature

4. A novelSERPINE1-FOSBfusion gene results in transcriptional up-regulation ofFOSBin pseudomyogenic haemangioendothelioma

5. Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benign and low-grade superficial endothelial cell neoplasms in the molecular era;Seminars in Diagnostic Pathology;2023-07

2. Catequentinib;Reactions Weekly;2022-03